Desmoglein as a target in skin disease and beyond

Journal of Investigative Dermatology

Volumn 132, Issue 3 PART 2, 2012, Pages 776-784

  Amagai, Masayuki ^a   Stanley, John R ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; DESMOGLEIN; DESMOGLEIN 1; DESMOGLEIN 2; DESMOGLEIN 3; DESMOGLEIN 4; EXFOLIATIN; PEMPHIGUS ANTIBODY; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

ADENOVIRUS; BLISTER; DESMOSOME; GENETIC ANALYSIS; HEART RIGHT VENTRICLE DYSPLASIA; HISTOPATHOLOGY; HUMAN; HYPOTRICHOSIS; IMMUNOLOGY; IMPETIGO BULLOSA; INTRACELLULAR SIGNALING; NONHUMAN; PALMOPLANTAR KERATODERMA; PATHOPHYSIOLOGY; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; REVIEW; SKIN DISEASE; STAPHYLOCOCCAL SCALDED SKIN SYNDROME; URINARY TRACT INFECTION;

EID: 84856909766     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.390     Document Type: Review

References (2)

1. Berkowitz, P., Hu, P., Warren, S., et al. 2006. p38MAPK inhibition prevents disease in pemphigus vulgaris mice. Proc Natl Acad Sci USA 103:12855-12860.
2. Nguyen, V.T., Arredondo, J., Chernyavsky, A.I., et al. 2004. Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes. J Biol Chem 279:2135-2146. (Corticosteroids may by therapeutic in pemphigus by increasing synthesis of desmogleins.)